Fate of inhaled monoclonal antibodies after the deposition of aerosolized particles in the respiratory system

Journal of Controlled Release

Volumn 196, Issue , 2014, Pages 344-354

  Guilleminault, L ^a,b,c   Azzopardi, N ^a   Arnoult, C ^a   Sobilo, J ^d   Herve V ^a,b   Montharu, J ^a   Guillon, A ^a,b,c   Andres, C ^c   Herault, O ^c   Le Pape, A ^d   Diot, P ^a,b,c   Lemarie E ^a,b,c   Paintaud, G ^a,c   Gouilleux Gruart, V ^a,c   Heuze Vourc'H N ^a,b  

^a UNIVERSITÉ DE TOURS   (France)

^b Université de Tours Centre d'Étude des Pathologies Respiratoires Inserm U1100   (France)

^c UNIVERSITY HOSPITAL OF TOURS   (France)

^d CNRS   (France)

Author keywords

FcRn; Monoclonal antibodies; Pharmacokinetics; Pulmonary delivery

Indexed keywords

BIOCHEMISTRY; BIOLOGICAL ORGANS; DEPOSITION; MAMMALS; MONOCLONAL ANTIBODIES; PHARMACOKINETICS; RESPIRATORY SYSTEM; SURFACE PLASMON RESONANCE; TISSUE;

BIOPHARMACEUTICALS; CHRONIC LUNG DISEASE; FCRN; INTRAVENOUS INJECTIONS; MONOCLONAL ANTIBODIES (MABS); PHARMACOKINETIC ANALYSIS; PULMONARY DELIVERY; TISSUE CONCENTRATIONS;

ANTIBODIES;

CETUXIMAB; AEROSOL; ANTINEOPLASTIC AGENT; FC RECEPTOR; FC RECEPTOR, NEONATAL; HLA ANTIGEN CLASS 1; MONOCLONAL ANTIBODY;

AEROSOL; AIRWAY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; LUNG CANCER; LUNG PARENCHYMA; MACACA; MEAN RESIDENCE TIME; MOUSE; NONHUMAN; RESPIRATORY SYSTEM; TRANSCYTOSIS; TRANSGENIC MOUSE; ANIMAL; BAGG ALBINO MOUSE; FEMALE; GENETICS; INHALATIONAL DRUG ADMINISTRATION; KNOCKOUT MOUSE; LUNG NEOPLASMS; MACACA FASCICULARIS; METABOLISM; NUDE MOUSE;

ADMINISTRATION, INHALATION; AEROSOLS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; LUNG NEOPLASMS; MACACA FASCICULARIS; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; MICE, NUDE; RECEPTORS, FC; RESPIRATORY SYSTEM;

EID: 84910020975     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2014.10.003     Document Type: Article

References (56)

1. P.E. Lipsky, D.M. van der Heijde, E.W. St Clair, D.E. Furst, F.C. Breedveld, and J.R. Kalden Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group N. Engl. J. Med. 343 2000 1594 1602 10.1056/NEJM200011303432202
2. A.M. Scott, J.D. Wolchok, and L.J. Old Antibody therapy of cancer Nat. Rev. Cancer 12 2012 278 287 10.1038/nrc3236
3. J.F. Colombel, W.J. Sandborn, W. Reinisch, G.J. Mantzaris, A. Kornbluth, and D. Rachmilewitz Infliximab, azathioprine, or combination therapy for Crohn's disease N. Engl. J. Med. 362 2010 1383 1395 10.1056/NEJMoa0904492
4. J.M. Reichert Antibodies to watch in 2014 MAbs 6 2014 5 14 10.4161/mabs.27333
5. A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu, and T. Murray Cancer statistics, 2008 CA Cancer J. Clin. 58 2008 71 96 10.3322/CA.2007.0010
6. A.D. Lopez, K. Shibuya, C. Rao, C.D. Mathers, A.L. Hansell, and L.S. Held Chronic obstructive pulmonary disease: current burden and future projections Eur. Respir. J. 27 2006 397 412 10.1183/09031936.06.00025805
7. B. Ley, H.R. Collard, and T.E. King Clinical course and prediction of survival in idiopathic pulmonary fibrosis Am. J. Respir. Crit. Care Med. 183 2011 431 440 10.1164/rccm.201006-0894CI
8. T. Koleba, and M.H.H. Ensom Pharmacokinetics of intravenous immunoglobulin: a systematic review Pharmacotherapy 26 2006 813 827 10.1592/phco.26.6.813
9. T.K. Hart, R.M. Cook, P. Zia-Amirhosseini, E. Minthorn, T.S. Sellers, and B.E. Maleeff Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys J. Allergy Clin. Immunol. 108 2001 250 257 10.1067/mai.2001.116576
10. T.T. Hansel, H. Kropshofer, T. Singer, J.A. Mitchell, and A.J.T. George The safety and side effects of monoclonal antibodies Nat. Rev. Drug Discov. 9 2010 325 338 10.1038/nrd3003
11. J. Boe, J.H. Dennis, B.R. O'Driscoll, T.T. Bauer, M. Carone, and B. Dautzenberg European Respiratory Society Guidelines on the use of nebulizers Eur. Respir. J. 18 2001 228 242
12. J. Vestbo, S.S. Hurd, A.G. Agustí, P.W. Jones, C. Vogelmeier, and A. Anzueto Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary Am. J. Respir. Crit. Care Med. 187 2013 347 365 10.1164/rccm.201204-0596PP
13. E.D. Bateman, S.S. Hurd, P.J. Barnes, J. Bousquet, J.M. Drazen, and M. FitzGerald Global strategy for asthma management and prevention: GINA executive summary Eur. Respir. J. 31 2008 143 178 10.1183/09031936.00138707
14. C.-E. Luyt, N. Bréchot, A. Combes, J.-L. Trouillet, and J. Chastre Delivering antibiotics to the lungs of patients with ventilator-associated pneumonia: an update Expert Rev. Anti-Infect. Ther. 11 2013 511 521 10.1586/eri.13.36
15. A.S. Michalopoulos Aerosolized antibiotics: the past, present and future, with a special emphasis on inhaled colistin Expert Opin. Drug Deliv. 9 2012 493 495 10.1517/17425247.2012.676039
16. D. Lightwood, V. O'Dowd, B. Carrington, V. Veverka, M.D. Carr, and M. Tservistas The discovery, engineering and characterisation of a highly potent anti-human IL-13 fab fragment designed for administration by inhalation J. Mol. Biol. 425 2013 577 593 10.1016/j.jmb.2012.11.036
17. A. Maillet, L. Guilleminault, E. Lemarié, S. Lerondel, N. Azzopardi, and J. Montharu The airways, a novel route for delivering monoclonal antibodies to treat lung tumors Pharm. Res. 28 2011 2147 2156 10.1007/s11095-011-0442-5
18. J. Hill, J.E. Eyles, S.J. Elvin, G.D. Healey, R.A. Lukaszewski, and R.W. Titball Administration of antibody to the lung protects mice against pneumonic plague Infect. Immun. 74 2006 3068 3070 10.1128/IAI. 74.5.3068-3070.2006
19. M.A. Poli, V.R. Rivera, M.L. Pitt, and P. Vogel Aerosolized specific antibody protects mice from lung injury associated with aerosolized ricin exposure Toxicon 34 1996 1037 1044
20. J. Hacha, K. Tomlinson, L. Maertens, G. Paulissen, N. Rocks, and J.-M. Foidart Nebulized anti-IL-13 monoclonal antibody Fab′ fragment reduces allergen-induced asthma Am. J. Respir. Cell Mol. Biol. 47 2012 709 717 10.1165/rcmb.2012-0031OC
21. J.V. Fahy, D.W. Cockcroft, L.P. Boulet, H.H. Wong, F. Deschesnes, and E.E. Davis Effect of aerosolized anti-IgE (E25) on airway responses to inhaled allergen in asthmatic subjects Am. J. Respir. Crit. Care Med. 160 1999 1023 1027 10.1164/ajrccm.160.3.9810012
22. S. Holgate, T. Casale, S. Wenzel, J. Bousquet, Y. Deniz, and C. Reisner The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation J. Allergy Clin. Immunol. 115 2005 459 465 10.1016/j.jaci.2004.11.053
23. N.E. Simister, and C.M. Story Human placental Fc receptors and the transmission of antibodies from mother to fetus J. Reprod. Immunol. 37 1997 1 23
24. K. Baker, S.-W. Qiao, T. Kuo, K. Kobayashi, M. Yoshida, and W.I. Lencer Immune and non-immune functions of the (not so) neonatal Fc receptor, FcRn Semin. Immunopathol. 31 2009 223 236 10.1007/s00281-009-0160-9
25. T.T. Kuo, K. Baker, M. Yoshida, S.-W. Qiao, V.G. Aveson, and W.I. Lencer Neonatal Fc receptor: from immunity to therapeutics J. Clin. Immunol. 30 2010 777 789 10.1007/s10875-010-9468-4
26. G.M. Spiekermann, P.W. Finn, E.S. Ward, J. Dumont, B.L. Dickinson, and R.S. Blumberg Receptor-mediated immunoglobulin G transport across mucosal barriers in adult life: functional expression of FcRn in the mammalian lung J. Exp. Med. 196 2002 303 310
27. A.J. Bitonti, J.A. Dumont, S.C. Low, R.T. Peters, K.E. Kropp, and V.J. Palombella Pulmonary delivery of an erythropoietin Fc fusion protein in non-human primates through an immunoglobulin transport pathway Proc. Natl. Acad. Sci. U. S. A. 101 2004 9763 9768 10.1073/pnas.0403235101
28. J.A. Dumont, A.J. Bitonti, D. Clark, S. Evans, M. Pickford, and S.P. Newman Delivery of an erythropoietin-Fc fusion protein by inhalation in humans through an immunoglobulin transport pathway J. Aerosol Med. 18 2005 294 303 10.1089/jam.2005.18.294
29. M. Sakagami, Y. Omidi, L. Campbell, L.E. Kandalaft, C.J. Morris, and J. Barar Expression and transport functionality of FcRn within rat alveolar epithelium: a study in primary cell culture and in the isolated perfused lung Pharm. Res. 23 2006 270 279 10.1007/s11095-005-9226-0
30. P.M. Smith-Jones, D. Solit, F. Afroze, N. Rosen, and S.M. Larson Early tumor response to Hsp90 therapy using HER2 PET: comparison with 18F-FDG PET J. Nucl. Med. 47 2006 793 796
31. S.E. Beck, B.L. Laube, C.I. Barberena, A.C. Fischer, R.J. Adams, and K. Chesnut Deposition and expression of aerosolized rAAV vectors in the lungs of Rhesus macaques Mol. Ther. 6 2002 546 554
32. N. Cézé, D. Ternant, F. Piller, D. Degenne, N. Azzopardi, and E. Dorval An enzyme-linked immunosorbent assay for therapeutic drug monitoring of cetuximab Ther. Drug Monit. 31 2009 597 601 10.1097/FTD.0b013e3181b33da3
33. R.J. Bauer, S. Guzy, and C. Ng A survey of population analysis methods and software for complex pharmacokinetic and pharmacodynamic models with examples AAPS J. 9 2007 E60 E83 10.1208/aapsj0901007
34. T. Jaki, and M.J. Wolfsegger Estimation of pharmacokinetic parameters with the R package PK Pharm. Stat. 10 2011 284 288 10.1002/pst.449
35. R Core Team R: A Language and Environment for Statistical Computing 2013 R Foundation for Statistical Computing Vienna, Austria (URL http://www.R-project.org/)
36. J. Mendelsohn, and J. Baselga Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer J. Clin. Oncol. 21 2003 2787 2799 10.1200/JCO.2003.01.504
37. N. Ledón, A. Casacó, E. Casanova, and I. Beausoleil Comparative analysis of binding affinities to epidermal growth factor receptor of monoclonal antibodies nimotuzumab and cetuximab using different experimental animal models Placenta 32 2011 531 534 10.1016/j.placenta.2011.04.008
38. S. Lerondel, and A. Le Pape Bioluminescence imaging in rodents: when light illuminates cancer research Curr. Mol. Imaging 2 2013 18 29 10.2174/2211555211302010004
39. A.J. Bitonti, and J.A. Dumont Pulmonary administration of therapeutic proteins using an immunoglobulin transport pathway Adv. Drug Deliv. Rev. 58 2006 1106 1118 10.1016/j.addr.2006.07.015
40. K.-J. Kim, T.E. Fandy, V.H.L. Lee, D.K. Ann, Z. Borok, and E.D. Crandall Net absorption of IgG via FcRn-mediated transcytosis across rat alveolar epithelial cell monolayers Am. J. Physiol. Lung Cell. Mol. Physiol. 287 2004 L616 L622 10.1152/ajplung.00121.2004
41. D.W. Nicholson, A. Ali, N.A. Thornberry, J.P. Vaillancourt, C.K. Ding, and M. Gallant Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis Nature 376 1995 37 43 10.1038/376037a0
42. X. Li, Y. Lu, T. Pan, and Z. Fan Roles of autophagy in cetuximab-mediated cancer therapy against EGFR Autophagy 6 2010 1066 1077 10.4161/auto.6.8.13366
43. J.H.E. Baker, K.E. Lindquist, L.A. Huxham, A.H. Kyle, J.T. Sy, and A.I. Minchinton Direct visualization of heterogeneous extravascular distribution of trastuzumab in human epidermal growth factor receptor type 2 overexpressing xenografts Clin. Cancer Res. 14 2008 2171 2179 10.1158/1078-0432.CCR-07-4465
44. D. Daydé, D. Ternant, M. Ohresser, S. Lerondel, S. Pesnel, and H. Watier Tumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20 Blood 113 2009 3765 3772 10.1182/blood-2008-08-175125
45. C.M. Lee, and I.F. Tannock The distribution of the therapeutic monoclonal antibodies cetuximab and trastuzumab within solid tumors BMC Cancer 10 2010 255 10.1186/1471-2407-10-255
46. S.I. Rudnick, J. Lou, C.C. Shaller, Y. Tang, A.J.P. Klein-Szanto, and L.M. Weiner Influence of affinity and antigen internalization on the uptake and penetration of Anti-HER2 antibodies in solid tumors Cancer Res. 71 2011 2250 2259 10.1158/0008-5472.CAN-10-2277
47. J.S. Patton Mechanisms of macromolecule absorption by the lungs Adv. Drug Deliv. Rev. 19 1996 3 36 10.1016/0169-409X(95)00113-L
48. J.S. Patton, C.S. Fishburn, and J.G. Weers The lungs as a portal of entry for systemic drug delivery Proc. Am. Thorac. Soc. 1 2004 338 344 10.1513/pats.200409-049TA
49. J.S. Patton, and P.R. Byron Inhaling medicines: delivering drugs to the body through the lungs Nat. Rev. Drug Discov. 6 2007 67 74 10.1038/nrd2153
50. C. Kliwinski, P.R. Cooper, R. Perkinson, J.R. Mabus, S.H. Tam, and T.M. Wilkinson Contribution of FcRn binding to intestinal uptake of IgG in suckling rat pups and human FcRn-transgenic mice Am. J. Physiol. Gastrointest. Liver Physiol. 304 2013 G262 G270 10.1152/ajpgi.00340.2012
51. N. Azzopardi, T. Lecomte, D. Ternant, M. Boisdron-Celle, F. Piller, and A. Morel Cetuximab pharmacokinetics influences progression-free survival of metastatic colorectal cancer patients Clin. Cancer Res. 17 2011 6329 6337 10.1158/1078-0432.CCR-11-1081
52. S.A. Antoniu Monoclonal antibodies for asthma and chronic obstructive pulmonary disease Expert. Opin. Biol. Ther. 13 2013 257 268 10.1517/14712598.2012.758247
53. R. Rafii, M.M. Juarez, T.E. Albertson, and A.L. Chan A review of current and novel therapies for idiopathic pulmonary fibrosis J. Thorac. Dis. 5 2013 48 73 10.3978/j.issn. 2072-1439.2012.12.07
54. Jitendra, P.K. Sharma, S. Bansal, and A. Banik Noninvasive routes of proteins and peptides drug delivery Indian J. Pharm. Sci 73 2011 367 375 10.4103/0250-474X.95608
55. S. Wenzel, D. Wilbraham, R. Fuller, E.B. Getz, and M. Longphre Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies Lancet 370 2007 1422 1431 10.1016/S0140-6736(07)61600-6
56. N. Roche, T. Chinet, and G. Huchon Ambulatory inhalation therapy in obstructive lung diseases Respiration 64 1997 121 130